Procter & Gamble Health Limited submitted its unaudited financial results for the quarter and half year ended September 30, 2026 to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Financial Figures - Quarterly Performance (Q2 FY27)
- Revenue from Operations: ₹38,249 lakhs (Q2 FY26: ₹32,492 lakhs; Q1 FY27: ₹36,371 lakhs)
- Other Income: ₹389 lakhs (Q2 FY26: ₹495 lakhs; Q1 FY27: ₹388 lakhs)
- Total Income: ₹38,638 lakhs (Q2 FY26: ₹32,987 lakhs; Q1 FY27: ₹36,759 lakhs)
- Profit Before Exceptional Items and Tax: ₹15,005 lakhs (Q2 FY26: ₹11,902 lakhs; Q1 FY27: ₹9,732 lakhs)
- Exceptional Items: None in Q2 FY27 (Q1 FY27: ₹3,180 lakhs gain from property sale)
- Profit Before Tax: ₹15,005 lakhs (Q2 FY26: ₹11,902 lakhs; Q1 FY27: ₹12,912 lakhs)
- Tax Expense: ₹3,854 lakhs (Q2 FY26: ₹3,048 lakhs; Q1 FY27: ₹3,297 lakhs)
- Net Profit: ₹11,151 lakhs (Q2 FY26: ₹8,854 lakhs; Q1 FY27: ₹9,615 lakhs)
- Earnings Per Share (Basic and Diluted): ₹67.18 (Q2 FY26: ₹53.34; Q1 FY27: ₹57.92)
Key Financial Figures - Half-Yearly Performance (H1 FY27)
- Revenue from Operations: ₹74,620 lakhs (H1 FY26: ₹66,366 lakhs; FY26: ₹140,797 lakhs)
- Other Income: ₹777 lakhs (H1 FY26: ₹898 lakhs; FY26: ₹1,734 lakhs)
- Total Income: ₹75,397 lakhs (H1 FY26: ₹67,264 lakhs; FY26: ₹142,531 lakhs)
- Profit Before Exceptional Items and Tax: ₹24,737 lakhs (H1 FY26: ₹20,783 lakhs; FY26: ₹44,986 lakhs)
- Exceptional Items: ₹3,180 lakhs gain (H1 FY26: None; FY26: None)
- Profit Before Tax: ₹27,917 lakhs (H1 FY26: ₹20,783 lakhs; FY26: ₹44,986 lakhs)
- Tax Expense: ₹7,151 lakhs (H1 FY26: ₹5,311 lakhs; FY26: ₹12,295 lakhs)
- Net Profit: ₹20,766 lakhs (H1 FY26: ₹15,472 lakhs; FY26: ₹32,691 lakhs)
- Earnings Per Share (Basic and Diluted): ₹125.09 (H1 FY26: ₹93.21; FY26: ₹196.94)
Exceptional Item Details
During the quarter ended June 30, 2026 (Q1 FY27), the Company sold its office premises property located at Worli for ₹3,334 lakhs. The carrying amount of the property as at date of sale was ₹154 lakhs. The gain arising from the sale amounting to ₹3,180 lakhs has been disclosed as an exceptional item.
Balance Sheet Highlights (as at September 30, 2026)
- Total Assets: ₹101,459 lakhs (March 31, 2026: ₹84,135 lakhs)
- Non-Current Assets: ₹29,454 lakhs (March 31, 2026: ₹28,509 lakhs)
- Current Assets: ₹72,005 lakhs (March 31, 2026: ₹55,626 lakhs)
- Cash and Cash Equivalents: ₹32,286 lakhs (March 31, 2026: ₹17,724 lakhs)
- Inventories: ₹13,689 lakhs (March 31, 2026: ₹13,665 lakhs)
- Trade Receivables: ₹17,580 lakhs (March 31, 2026: ₹16,426 lakhs)
- Total Equity: ₹65,805 lakhs (March 31, 2026: ₹52,455 lakhs)
- Equity Share Capital: ₹1,660 lakhs (unchanged from March 31, 2026)
- Other Equity: ₹64,145 lakhs (March 31, 2026: ₹50,795 lakhs)
- Current Liabilities: ₹29,685 lakhs (March 31, 2026: ₹25,493 lakhs)
- Trade Payables: ₹23,101 lakhs (including ₹426 lakhs due to micro and small enterprises)
Cash Flow Statement (Six months ended September 30, 2026)
- Cash from Operating Activities: ₹19,086 lakhs (H1 FY26: ₹17,223 lakhs)
- Cash from Investing Activities: ₹3,173 lakhs (H1 FY26: ₹141 lakhs)
- Cash from Financing Activities: (₹7,697) lakhs (H1 FY26: (₹7,634) lakhs)
- Net Increase in Cash: ₹14,562 lakhs (H1 FY26: ₹9,729 lakhs)
- Dividend Paid: ₹7,470 lakhs (same as H1 FY26)
Additional Information
- The Company has identified Pharmaceuticals as its single primary reportable segment
- No subsidiary, associate or joint venture as at September 30, 2026
- Financial results prepared in accordance with Indian Accounting Standards (Ind AS)
- Results reviewed by Audit Committee and approved by Board of Directors
- Limited review conducted by statutory auditors Haribhakti & Co. LLP who issued an unmodified conclusion
- Previous year's figures have been regrouped/rearranged/reclassified where necessary